(S (NP (NP (NNP Predicting)) (NP (NP (DT the) (NN response)) (PP (IN of) (NP (NP (DT a) (JJ specific) (NN cancer)) (PP (IN to) (NP (DT a) (NN therapy))))))) (VP (VBZ is) (NP (NP (DT a) (JJ major) (NN goal)) (PP (IN in) (NP (NP (JJ modern) (NN oncology)) (SBAR (WHNP (WDT that)) (S (VP (MD should) (ADVP (RB ultimately)) (VP (VB lead) (PP (IN to) (NP (DT a) (VBN personalised) (NN treatment))))))))))) (. .))
(S (NP (NP (NML (JJ High) (HYPH -) (NN throughput)) (NNS screenings)) (PP (IN of) (NP (NP (ADJP (RB potentially) (JJ active)) (NNS compounds)) (PP (IN against) (NP (NP (DT a) (NN panel)) (PP (IN of) (NP (ADJP (RB genomically) (JJ heterogeneous)) (NML (NN cancer) (NN cell)) (NNS lines)))))))) (VP (VBP have) (VP (VBN unveiled) (NP (NP (JJ multiple) (NNS relationships)) (PP (IN between) (NP (NP (JJ genomic) (NNS alterations)) (CC and) (NP (NN drug) (NNS responses))))))) (. .))
(S (NP (JJ Various) (JJ computational) (NNS approaches)) (VP (VBP have) (VP (VBN been) (VP (VBN proposed) (S (VP (TO to) (VP (VB predict) (NP (NN sensitivity)) (PP (VBN based) (PP (IN on) (NP (JJ genomic) (NNS features))))))) (, ,) (SBAR (IN while) (S (NP (NNS others)) (VP (VBP have) (VP (VBN used) (NP (NP (DT the) (NN chemical) (NNS properties)) (PP (IN of) (NP (DT the) (NNS drugs)))) (S (VP (TO to) (VP (VB ascertain) (NP (PRP$ their) (NN effect)))))))))))) (. .))
(S (PP (IN In) (NP (DT an) (NN effort) (S (VP (TO to) (VP (VB integrate) (NP (DT these) (JJ complementary) (NNS approaches))))))) (, ,) (NP (PRP we)) (VP (VBD developed) (NP (NML (NN machine) (NN learning)) (NNS models)) (S (VP (TO to) (VP (VB predict) (NP (NP (DT the) (NN response)) (PP (IN of) (NP (NML (NN cancer) (NN cell)) (NNS lines)))) (PP (IN to) (NP (NP (NN drug) (NN treatment)) (, ,) (VP (VBN quantified) (PP (IN through) (NP (NN IC50) (NNS values))) (, ,) (PP (VBN based) (PP (IN on) (NP (CC both) (NP (NP (DT the) (JJ genomic) (NNS features)) (PP (IN of) (NP (DT the) (NN cell) (NNS lines)))) (CC and) (NP (NP (DT the) (NN chemical) (NNS properties)) (PP (IN of) (NP (DT the) (VBN considered) (NNS drugs)))))))))))))) (. .))
(S (NP (NNS Models)) (VP (VBD predicted) (NP (NN IC50) (NNS values)) (PP (IN in) (NP (NP (DT a) (JJ 8-fold) (NN cross-validation)) (CC and) (NP (DT an) (JJ independent) (JJ blind) (NN test)))) (PP (IN with) (NP (NP (NN coefficient)) (PP (IN of) (NP (NP (NN determination) (NN R2)) (PP (IN of) (NP (CD 0.72) (CC and) (CD 0.64))) (ADVP (RB respectively))))))) (. .))
(S (ADVP (RB Furthermore)) (, ,) (NP (NNS models)) (VP (VBD were) (ADJP (JJ able) (S (VP (TO to) (VP (VB predict) (PP (IN with) (NP (JJ comparable) (NN accuracy) (PRN (-LRB- -LRB-) (NP (NP (NN R2)) (PP (IN of) (NP (CD 0.61)))) (-RRB- -RRB-)))) (NP (NP (NNS IC50s)) (PP (IN of) (NP (NP (NN cell) (NNS lines)) (PP (IN from) (NP (NP (DT a) (NN tissue)) (VP (RB not) (VBN used) (PP (IN in) (NP (DT the) (NN training) (NN stage)))))))))))))) (. .))
(S (NP (PRP$ Our) (ADJP (FW in) (FW silico)) (NNS models)) (VP (MD can) (VP (VB be) (VP (VBN used) (S (VP (TO to) (VP (VB optimise) (NP (NP (DT the) (JJ experimental) (NN design)) (PP (IN of) (NP (NML (NN drug) (HYPH -) (NN cell)) (NNS screenings)))) (PP (IN by) (S (VP (VP (VBG estimating) (NP (NP (DT a) (JJ large) (NN proportion)) (PP (IN of) (NP (VBG missing) (NN IC50) (NNS values))))) (CONJP (RB rather) (IN than)) (ADVP (RB experimentally)) (VP (VB measure) (NP (PRP them)))))))))))) (. .))
(S (S (NP (NP (DT The) (NNS implications)) (PP (IN of) (NP (PRP$ our) (NNS results)))) (VP (VBP go) (PP (IN beyond) (NP (NML (JJ virtual) (NN drug)) (NN screening) (NN design))))) (: :) (S (ADVP (RB potentially)) (NP (NP (NNS thousands)) (PP (IN of) (NP (NNS drugs)))) (VP (MD could) (VP (VB be) (VP (VBN probed) (ADVP (FW in) (FW silico)) (S (VP (TO to) (ADVP (RB systematically)) (VP (VB test) (NP (PRP$ their) (JJ potential) (NN efficacy)) (PP (IN as) (NP (JJ anti-tumour) (NNS agents))) (PP (VBN based) (PP (IN on) (NP (PRP$ their) (NN structure)))) (, ,) (S (ADVP (RB thus)) (VP (VP (VBG providing) (NP (DT a) (JJ computational) (NN framework)) (S (VP (TO to) (VP (VB identify) (NP (JJ new) (NN drug)) (S (VP (VBG repositioning) (NP (NNS opportunities)))))))) (CONJP (RB as) (RB well) (IN as)) (ADVP (RB ultimately)) (VP (VB be) (ADJP (JJ useful) (PP (IN for) (NP (JJ personalized) (NN medicine)))) (PP (IN by) (S (VP (VBG linking) (NP (NP (DT the) (JJ genomic) (NNS traits)) (PP (IN of) (NP (NNS patients)))) (PP (IN to) (NP (NN drug) (NN sensitivity)))))))))))))))) (. .))
